


**CLAIMS**

We claim:

1. (cancelled) A composition of matter comprising a compound of formula I



in which

$R^1$  is methyl, ethyl, propyl, or butyl;

$R^2$  is H, -OH, -NH<sub>2</sub>, or -NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

$R^3$  is a saccharide residue, disaccharide residue, trisaccharide residue, or tetrasaccharide residue, wherein the saccharide residue, disaccharide residue, trisaccharide residue or tetrasaccharide residue is optionally substituted one or more times by a saccharide protective group; or  
amino acid residue, diamino acid residue, triamino acid residue, or tetraamino acid residue, wherein the amino acid residue, diamino acid residue, triamino acid residue or tetraamino acid residue is optionally substituted one or more times by an amino acid protective group;

$R^4$  is methyl, ethyl, propyl, or butyl;

$R^5$  is methyl, ethyl, propyl, or butyl;

$Z$  is  $-(C=O)_n-C_1-C_{16}$ -alkyl-,  $-(C=O)_n-C_1-C_{16}$ -alkyl-NH-,  $-(C=O)_n-C_6-C_{16}$ -alkyl-,  $-(C=O)_n-C_6-C_{16}$ -alkyl-NH-,  $-(C=O)_n-C_1-C_{16}$ -alkyl-O-,  $-(C=O)_n-C_1-C_{16}$ -alkyl-(C=O)<sub>m</sub>-, or a covalent bond;  $-(C=O)_n-C_6-C_{16}$ -alkyl-O-,  $-(C=O)_n-C_6-C_{16}$ -alkyl-(C=O)<sub>m</sub>-, or a covalent bond;

n is 0 or 1; and

m is 0 or 1; or

a pharmaceutically acceptable salt or physiologically functional derivative thereof, with at least one other active ingredient, or a pharmaceutically acceptable salt or physiologically functional derivative thereof.

2. (cancelled) The composition of matter according to claim 1, wherein

R<sup>1</sup> ethyl, propyl, or butyl; and

R<sup>3</sup> is a saccharide residue, or disaccharide residue, wherein the saccharide residue or disaccharide residue is optionally substituted one or more times by a saccharide protective group; or amino acid residue, or diamino acid residue, wherein the amino acid residue or diamino acid residue is optionally substituted one or more times by an amino acid protective group; or

a pharmaceutically acceptable acid addition salt thereof.

3. (cancelled) The composition of matter according to claim 1, wherein

R<sup>1</sup> ethyl;

R<sup>2</sup> OH;

R<sup>3</sup> is a saccharide residue, wherein the saccharide residue is optionally substituted one or more times by a saccharide protective group; diamino acid residue, wherein the diamino acid residue is optionally substituted one or more times by an amino acid protective group;


R<sup>4</sup> methyl;

R<sup>5</sup> methyl; and

Z -(C=O)-C<sub>0</sub>-C<sub>4</sub>-alkyl, a covalent bond; or

a pharmaceutically acceptable acid addition salt thereof.

4. (cancelled) The composition of matter according to one of claims 1 to 3, wherein the other active ingredient is an antidiabetic, hypoglycemic active ingredient, HMG-CoA reductase inhibitor, cholesterol absorption inhibitor, PPAR gamma agonist, PPAR alpha agonist, PPAR alpha/gamma agonist, fibrate, MTP inhibitor, bile acid absorption inhibitor, CETP inhibitor, polymeric bile acid adsorbent, LDL receptor inducer, ACAT inhibitor, antioxidant, lipoprotein lipase inhibitor, ATP-citrate lyase inhibitor, squalene synthetase inhibitor, lipoprotein(a) antagonist, lipase inhibitor, insulin, sulfonylurea, biguanide, meglitinide, thiazolidinedione,  $\alpha$ -glucosidase inhibitor, active ingredient acting on the ATP-dependent potassium channel of the beta cells, CART agonist, NPY agonist, MC4 agonist, orexin agonist, H3 agonist, TNF agonist, CRF agonist, CRF BP antagonist, urocortin agonist,  $\beta$ 3 agonist, MSH (melanocyte-stimulating hormone) agonist, CCK agonist, serotonin reuptake inhibitor, mixed serotonergic and noradrenergic compound, 5HT agonist, bombesin agonist, galanin antagonist, growth hormone, growth hormone-releasing compound, TRH agonist, uncoupling protein 2 or 3 modulator, leptin agonist, DA agonist, lipase/amylase inhibitor, PPAR modulator, RXR modulator, TR- $\beta$  agonist or amphetamine.
5. (cancelled) The composition of matter according to one of claims 1 to 3, wherein the other active ingredient is a compound that normalizes lipid metabolism.
6. (cancelled) The composition of matter according to one of claims 1 to 3, wherein the other active ingredient is a compound that normalizes lipid metabolism selected from the group consisting of statins, glitazones, PPAR alpha agonists, cholestyramine, colestipol, colessevelam, adsorbent resins, fibrates, gemfibrozil, cholesterol absorption inhibitors, ezetimibe, tiqueside, pamaqueside, CETP inhibitors, MTP inhibitors, LDL receptor inducers, lipase inhibitors, and orlistat.
7. (cancelled) The composition of matter according to one of claims 1 to 3, wherein the other active ingredient is a cholesterol absorption inhibitor.
8. (cancelled) The composition of matter according to claim 7, wherein the cholesterol absorption inhibitor is ezetimibe, tiqueside or pamaqueside.
9. (currently amended) A composition of matter comprising a compound of formula I



In which

$R^1$  is methyl, ethyl, propyl, or butyl;

$R^2$  is H, -OH, -NH<sub>2</sub>, or -NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

$R^3$  is a saccharide residue, disaccharide residue, trisaccharide residue, or tetrasaccharide residue, wherein the saccharide residue, disaccharide residue, trisaccharide residue or tetrasaccharide residue is optionally substituted one or more times by a saccharide protective group; or  
amino acid residue, diamino acid residue, triamino acid residue, or tetraamino acid residue, wherein the amino acid residue, diamino acid residue, triamino acid residue or tetraamino acid residue is optionally substituted one or more times by an amino acid protective group;

$R^4$  is methyl, ethyl, propyl, or butyl;

$R^5$  is methyl, ethyl, propyl, or butyl;

Z is -(C=O)<sub>n</sub>-C<sub>n</sub>-C<sub>1-6</sub>-alkyl-, -(C=O)<sub>n</sub>-C<sub>n</sub>-C<sub>1-6</sub>-alkyl-NH-,  
-(C=O)<sub>n</sub>-C<sub>n</sub>-C<sub>1-6</sub>-alkyl-O-, -(C=O)<sub>n</sub>-C<sub>1</sub>-C<sub>1-6</sub>-alkyl-(C=O)<sub>m</sub>-, or a covalent bond;

n is 0 or 1; and

m is 0 or 1; or

a pharmaceutically acceptable salt or physiologically functional derivative thereof, with at least one other active ingredient, or a pharmaceutically acceptable salt or physiologically functional derivative thereof, wherein the other active ingredient is selected from ezetimibe and

~~The composition of matter according to one of claims 1 to 3, comprising Caromax® as other active ingredient.~~

10. (currently amended) A method for effecting the prophylaxis or treatment of a lipid metabolism disorder or metabolic syndrome in a patient comprising administering a pharmaceutically effective amount of the composition of matter according to claim 9 ~~one of claims 1 to 3~~ to the patient.

11. (original) The method of claim 10 wherein the pharmaceutically effective amount of the composition of matter is provided for by the combination of a pharmaceutically effective amount or a subclinical pharmaceutically effective amount of the compound of formula I and a pharmaceutically effective amount or a subclinical pharmaceutically effective amount of the other active ingredient of the composition of matter, such that the combination results in the amount of the composition of matter being pharmaceutically effective.

12. (currently amended) A method for effecting the prophylaxis or treatment of hyperlipidemia in a patient comprising administering a pharmaceutically effective amount of the composition of matter according to claim 9 ~~one of claims 1 to 3~~ to the patient.

13. (original) The method of claim 12 wherein the pharmaceutically effective amount of the composition of matter is provided for by the combination of a pharmaceutically effective amount or a subclinical pharmaceutically effective amount of the compound of formula I and a pharmaceutically effective amount or a subclinical pharmaceutically effective amount of the other active ingredient of the composition of matter, such that the combination results in the amount of the composition of matter being pharmaceutically effective.

14. (currently amended) A method for effecting the prophylaxis or treatment of arteriosclerotic manifestations in a patient comprising administering a pharmaceutically effective amount of the composition of matter according to claim 9 ~~one of claims 1 to 3~~ to the patient.

15. (original) The method of claim 14 wherein the pharmaceutically effective amount of the composition of matter is provided for by the combination of a pharmaceutically effective amount or a subclinical pharmaceutically effective amount of the compound of formula I and a pharmaceutically effective amount or a subclinical pharmaceutically effective amount of the other active ingredient of the composition of matter, such that the combination results in the amount of the composition of matter being pharmaceutically effective.

16. (currently amended) A method for effecting the prophylaxis or treatment of a physiological condition as described herein in a patient comprising administering a pharmaceutically effective amount of the composition of matter according to claim 9 ~~one of claims 1 to 3~~ to the patient whereby

the administering is effected by administering the compound of formula I and the other active ingredient of the composition of matter closely in time.

17. (original) The method of claim 16 wherein closely in time means within 10 minutes.

18. (currently amended) A method for effecting the prophylaxis or treatment of a lipid metabolism disorder in a patient comprising administering a pharmaceutically effective amount of the composition of matter according to claim 9 ~~one of claims 1 to 3~~ to the patient whereby the administering is effected by administering the compound of formula I and the other active ingredient of the composition of matter closely in time.

19. (original) The method of claim 18 wherein closely in time means within 10 minutes.

20. (currently amended) A pharmaceutical composition comprising, a pharmaceutically acceptable carrier, and a pharmaceutically effective amount or a subclinical pharmaceutically effective amount of the compound of formula I according to claim 9 ~~one of claims 1 to 3~~ and a pharmaceutically effective amount or a subclinical pharmaceutically effective amount of the other active ingredient of the composition of matter, such that the combination results in the amount of the composition of matter being pharmaceutically effective.

21. (currently amended) A process for producing a pharmaceutical composition of the composition of matter as claimed in claim 9 ~~one of claims 1 to 3~~, comprising mixing the compound of formula I and the other active ingredient of the composition of matter with a pharmaceutically suitable carrier and converting this mixture into a form suitable for administration.